ScreenerHero

ICCCImmuCell Corporation

NAS · US · Healthcare · Biotechnology · immucell.com
10.06USD-0.69%Mkt Cap: 91.37M $P/E: 143.71

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
ImmuCell (ICCC) Q2 2026 Earnings Call Transcript

Product sales hit $7.2 million as market share climbed to 19% amid capacity expansion plans.

Motley Fool
ImmuCell Corp (ICCC) (Q2 2026) Earnings Call Highlights: Record Net Income and Market Share ...

ImmuCell Corp (ICCC) reports 11.5% sales growth and a 19% U.S. market share, while investing $8 million to triple manufacturing capacity.

GuruFocus.com
ImmuCell Q2 Earnings Call Highlights

ImmuCell (NASDAQ:ICCC) reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027. Product sales rose 11.5% year ove

MarketBeat
ImmuCell Corporation Q2 2026 Earnings Call Summary

Moby summary of ImmuCell Corporation's Q2 2026 earnings call

Moby
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
Zacks
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
Zacks
Top Stock Reports for JPMorgan, Novartis & Qualcomm
Zacks
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
Zacks
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
Zacks